Within the autoimmune space, payers face difficult challenges in decision making. This category has non-exhaustive and non-exclusive populations, making management by indication burdensome.
This has been an exciting week for gene therapy in the U.S. market. With the approval of Novartis’ novel CAR-T gene therapy, and a launch price below analyst expectations, there is uncertainty around the pricing expectations for future pipeline agents.
With recent disruptive pricing in the HCV market, will lower cost therapies take share from legacy treatments? Preview what payers forecast back in the second half of 2016 with our M Tracker data.
With the evolution of payer management in different specialty classes, MKO has been tracking management priority and budget impact using our M Tracker. M Tracker has revealed a significant change in oncology and HCV management in the first half of 2017.
Two of the biggest pharmaceutical companies, Pfizer Inc. and GlaxoSmithKline, are significantly reducing spending with doctors for events at which doctors make presentations to their peers.
Both the FDA and the EMA are showing increasing levels of support for biosimilars, while physician resistance is declining in both the US and Europe. Cost is a big driver, among other factors.
